JAZZ vs VRTX: fair value comparison
Jazz Pharmaceuticals plc and Vertex Pharmaceuticals Incorporated · Updated 2026-08-31
Both currently screen as fairly valued on TickrTrends' Forward Fair Value model. Within Healthcare, VRTX currently sits closer to the top of our discount ranking. VRTX carries the stronger quality grade. JAZZ carries the stronger momentum grade.
| JAZZ | VRTX | |
|---|---|---|
| Verdict | Fairly valued | Fairly valued |
| Last price | $251.58 | $541.69 |
| 12-month range | $129.66–$251.58 | $401.00–$486.03 |
| Sector rank | #84 of 113 Healthcare | #81 of 113 Healthcare |
| Quality grade | B | A |
| Momentum grade | A | B |
| Leverage | Moderate | Low |
| Margin trend | Stable | Stable |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | Fairly Valued | Overvalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: JAZZ fair value analysis · VRTX fair value analysis